Country: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
CLOTRIMAZOLE (UNII: G07GZ97H65) (CLOTRIMAZOLE - UNII:G07GZ97H65), BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)
Actavis Pharma, Inc.
CLOTRIMAZOLE
CLOTRIMAZOLE 10 mg in 1 g
TOPICAL
PRESCRIPTION DRUG
Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. None. Risk Summary There are no available data on topical betamethasone dipropionate or clotrimazole use in pregnant women to identify a clotrimazole and betamethasone dipropionate cream associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of potent or very potent topical corticosteroid during pregnancy. Advise pregnant women that clotrimazole and betamethasone dipropionate cream may increase the risk of having a low birthweight infant and to use clotrimazole and betamethasone dipropionate cream on the smallest area of skin and for the shortest
Clotrimazole and betamethasone dipropionate cream, USP is available as follows: 15 gram tube in a carton (NDC 0472-0379-15) 45 gram tube in a carton (NDC 0472-0379-45) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Abbreviated New Drug Application
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE- CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM ACTAVIS PHARMA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM. CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM, FOR TOPICAL USE INITIAL U.S. APPROVAL: 1984 INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to _Epidermophyton floccosum,_ _Trichophyton mentagrophytes, _and_ Trichophyton rubrum_ in patients 17 years and older. (1) DOSAGE AND ADMINISTRATION _Tinea pedis: _Apply a thin film to the affected skin areas twice a day for 2 weeks. Do not use longer than 4 weeks. (2) _Tinea cruris and tinea corporis: _Apply a thin film to the affected skin area twice a day for 1 week. Do not use longer than 2 weeks. (2) Do not use with occlusive dressings unless directed by a physician. (2) Not for ophthalmic, oral or intravaginal use. (2) DOSAGE FORMS AND STRENGTHS Cream, 1%/0.05% (base) (3) Each gram of clotrimazole and betamethasone dipropionate cream contains 10 mg of clotrimazole and 0.64 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Clotrimazole and betamethasone dipropionate cream can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of the treatment. Risk factor(s) are: use of high-potency topical corticosteroid, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and young age. Modify use should HPA axis suppression develop. (5.1 সম্পূর্ণ নথি পড়ুন